Product
Dendritic Cell Infusion and Immune Checkpoint Inhibitor
1 clinical trial
1 indication
Indication
Pancreatic CancerClinical trial
A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard ChemotherapyStatus: Not yet recruiting, Estimated PCD: 2024-12-31